Abstract: In a method for recovering lithium hydroxide from a lithium secondary battery, cathode powder is prepared from a cathode of the lithium secondary battery. A cathode active material mixture is prepared by mixing the cathode powder with a calcium compound. The cathode active material mixture is reduced to form a preliminary precursor mixture. A lithium precursor is recovered from the preliminary precursor mixture. Therefore, a lithium precursor can be obtained with high purity without a complicated leaching process or an additional process, which result from a wet-based acid solution process.

Abstract: The present disclosure relates to a catalyst for a fuel cell electrode including an active particle which includes a core comprising platinum, a transition metal excluding platinum, and an oxide of a non-transition metal; and a shell disposed on the core and including platinum, wherein the active particle includes platinum and the non-transition metal in a molar ratio of 100:1.80 to 100:4.00, a method of preparing the same, and a fuel cell including the same.

Abstract: An automatic replacement device of a secondary battery material including reel support parts to support a supply reel; a material support part spaced apart from the reel support part; clamping parts, each including a clamping roller to come into contact with the material when replacing the supply reel, a vacuum suction part to suction the material by vacuum, a clamping frame to rotatably support the clamping roller and the vacuum suction part, and a cutter to cut the material when coming into contact with the material; first drive parts to move the clamping roller toward/away from the material; and second drive parts to move the cutter toward/away from the material, wherein the automatic replacement device cuts the material as the material is suctioned to the vacuum suction part after being adhered to a material wound around a replacement supply reel when the supply reel is replaced.

Abstract: Provided is a modified iduronate-2-sulfatase (IDS) gene constructed by inserting the nucleotide of SEQ ID NO: 2 into a wild-type IDS gene. In addition to being negatively charged, the improved IDS enzyme encoded by the modified gene exhibits a sufficient retention time in blood to target the bone, so that it is more effective for treating Hunter syndrome.

Abstract: Provided is a modified iduronate-2-sulfatase (IDS) gene constructed by inserting the nucleotide of SEQ ID NO: 2 into a wild-type IDS gene. In addition to being negatively charged, the improved IDS enzyme encoded by the modified gene exhibits a sufficient retention time in blood to target the bone, so that it is more effective for treating Hunter syndrome.

Abstract: A use of an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease, a method for preventing or treating an NMDA receptor hypofunction-related disease in a subject, which comprises administering a therapeutically effective amount of an inhalable powder formulation comprising growth hormone (GH) to the subject in need thereof, and an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease comprising GH as an active ingredient are provided.

Abstract: Disclosed is a modified iduronate-2-sulfatase (IDS) gene constructed by inserting the nucleotide of SEQ ID NO: 2 into a wild-type IDS gene. In addition to being negatively charged, the improved IDS enzyme encoded by the modified gene exhibits a sufficient retention time in blood to target the bone, so that it is more effective for treating Hunter syndrome.